Innovative Products that Enhance Quality of Life
Lamicare is an innovator of scientifically developed, natural-based, proprietary pharmaceutical products developed to enhance human health and wellbeing on a global basis.
We develop, formulate and bring to market our own line of branded products, including over-the-counter topical creams, skincare and hair and scalp treatment products, as well as nutritional supplements that we market globally through a network of regional distributors and wholesalers.
Overview
Our company was founded in September 2008 through an acquisition of the IP rights to an innovative Psoriasis and Eczema treatment range that was developed by our Research Director, Dr. Nigel Christie, who holds a Doctorate in Marine Biology.
His studies over the years have shown that the seaweed cream preparation, now branded as Dermikelp™, has a remarkable rate of efficacy on Psoriasis and Eczema sufferers, and provides and effective alternative to widely prescribed Cortisone treatments. As Cortisone is a short-term treatment plan with known side effects, our Dermikelp range offers sufferers a natural, chemical free alternative that is indicated for long-term treatment and has an excellent safety profile.
In January 2009, we actively started the commercialization process of the Dermikelp product range, consisting of Skin, Nutritional Supplements and Hair treatments targeting the Dermatitis category with special focus on Psoriasis and Eczema conditions. In August 2009 we launched the first phase of our South African rollout strategy, through a 12 month Proof-of-Concept, which we completed in June 2010.
Strategy
Research &
Development
Investors
Our global distribution strategy is two fold: a) to setup regional distribution partnerships with companies that can take our products to market in the most effective manner possible, and b) to leverage opportunities in the ever growing internet online buying arena.
We also intend to source and engage relevant partners in all viable territories, with the short-term emphasis being to establish the brand in the USA, Europe and Africa.
The strategy therefore is to focus upon leveraging our intellectual property portfolio and expanding its opportunities into broader areas within dermatological consumer healthcare markets.
Our branded products are distributed through Pharmaceutical wholesalers and distributors in each region that we are registered to sell our products. (Currently South Africa with pending registrations in Sub-Saharan Africa)
To be truly effective in its long-term marketing and distribution efforts, the Company develops products that are efficacious, novel, proprietary and in certain cases, patentable.
By producing effective products with solid science, the Company is able to cater to the needs of informed individuals.
Our approach consists of:
It is our belief that efficacious products with strong science, quality service to consumers, and product recognition are the ingredients necessary for this marketing and distribution approach to be successful.
Research & Development
To capitalize on the early successes of the Dermikelp range, we are in the process of developing line extensions to our skin and hair care treatment range that will be marketed and distributed via the same channels that the current range is being sold into, namely, retail pharmacies, pharmacy chain stores Internet on-line shopping to service the global market.
We aim to invest in our research and development business, focusing on topical skin care innovations, unique treatments for hair and scalp disorders, and professional hair and skin care range for the consumer healthcare and pharmaceutical markets.
We are currently at pre-launch phase of our new Lamicare Professional range of Skin and Hair products that will be targeted at professional hair and beauty salons. This range is developed with the same active ingredient, Cellburst Ecklonia Maxima, which has been used to great effect in our Dermikelp range. This product range will provide entry into the professional hair and beauty market that would not be able to be penetrated by Dermikelp due to its positioning as a pharmaceutical range.
Management
HOLDING COMPANY
President and CEO: Mr. Franco Maccioni
CFO & International Business Development: Mr. Christopher Thornblom
VP Research & Development: Dr. Nigel Christie PhD
SOUTH AFRICA OPERATIONAL HEAD OFFICE
Executive
Managing Director: Mr. Franco Maccioni
Company Secretary: Ms. Cristen Ashley-Williams
Financial manager (Outsourced): Mrs. Michelle Welton CFA
Operations
Operations Manager: Mr. Lee Glanville
Responsible Pharmacist (Outsourced) Mr. James Gibson (B.Pharm, MBA)
If you would like to request more information on the company, please complete the form below.
Dermikelp™ Dermatological treatment range. Indicated for Psoriasis, Eczema and other problem skin conditions.
Lamicare® Professional - Currently launching with Detoxifying formulation capsules, Shampoo & Conditioner and Scalp penetrating Cellburst gel. This brand will have line extensions that will include face and hand cream for sensitive skin types, body-wash, and more.
Oceanique® - Everyday, Home Spa and Mens range.
News
June 2010 - First product shipped to Nu Clicks Pharmacy stores as part of trial phase.
May 2010 - Dis-chem extended trial by adding a further 20 stores nationally to our listing footprint.
April 2010 - Nu Clicks Pharmacy, one of the largest retail pharmacy chains in South Africa (over 220 stores), approves a trial listing of Dermikelp products in the OTC section of their pharmacy in 6 of their mega-stores (2 in Cape Town and 4 in Johannesburg).
September 2009 Feb 2010 - Established national sales force (reps and agency) to provide customer awareness (Pharmacy level) and to sell product into trade. Implimented limited period national advertising trial in mainstream weekly publication, with very encouraging results.
August 2009 - Secured national listing with United Pharmaceutical Distributors (UPD).
July 2009 - Secured listing with Alpha-Pharm Eastern Cape.
June 2009 - Sales reps appointed and started sales process into pharmacy in Western Cape. Secured listing with Dis-Chem on trial phase in Western Cape (5 Stores).
May 2009 - Products listed with Alpha-Pharm Western Cape wholesaler. Product range first production run completed and delivered to Lamicare for release to SA market.
March 2009 - Product range issued with NAPPI codes and packaging designs and prototypes completed and submitted to printers and packaging companies for 1st production run.
February to March 2009 - Appointed responsible pharmacist and outsourced GMP compliant production facilities. Products registered with South African Medicines Control Council (MCC). Dossiers submitted to MediKredit for registration with SA Medical Aid Societies.
November 2008 through January 2009 - Product range development and branding, Dermikelp trademark registered in South Africa.
October 2008 - South African and USA subsidiaries registered and commenced business.
September 2008 - Business started through acquisition of rights to Kelp based eczema & psoriasis formulation.
Contact
LAMICARE SA (PTY) LTD
1st Floor, Foyer 3, Colosseum Building
Century City, Cape Town, 7441
PO Box 20089, Big Bay, 7448
South Africa
LAMICARE INCORPORATED
10685-B Hazelhurst Dr #9362
Houston, Texas
TX-77043
USA
Disclaimer
